放射免疫治疗(RIT)用于滤泡性淋巴瘤在一线及复发时均实现长期淋巴瘤控制:国际RIT登记处281例患者8年随访数据
国际RIT登记处281例滤泡性淋巴瘤患者接受放射免疫治疗,中位随访8.2年。一线治疗者8年无进展生存(PFS)为53.6%,复发治疗者为29.6%;一线者中位PFS和总生存(OS)均未达到,且显著优于复发治疗者。RIT是一线和复发时安全有效的治疗选择。
要点
- 一线RIT后完全缓解率76.9%,复发RIT后完全缓解率48.5%。
- 整体8年PFS为33.9%,一线53.6% vs 复发29.6%。
- 35例(12.5%)发生第二恶性肿瘤,16例(5.7%)转化为侵袭性淋巴瘤。
核心结论
- RIT是滤泡性淋巴瘤一线和复发时安全有效的治疗选择,8年PFS分别为53.6%和29.6%。
研究设计与样本
- 分析国际RIT登记处(RIT Network)收集的281例接受RIT的滤泡性淋巴瘤患者数据,RIT后中位随访8.2年。
主要发现
- 一线RIT后完全缓解76.9%、部分缓解9.6%、疾病稳定1.9%、疾病进展1.9%,9.7%未记录疗效。
- 复发RIT后完全缓解48.5%、部分缓解16.6%、疾病稳定2.6%、疾病进展10.5%,21.8%未记录疗效。
- 中位随访8.2年,全部患者中位PFS为2.54年,中位OS未达到。
- 一线RIT的中位PFS和OS均未达到,显著优于复发RIT(PFS 2.11年,OS 10.8年;P=0.0037和P=0.0021)。
- 整体8年PFS为33.9%,一线53.6% vs 复发29.6%;整体8年OS为58.8%,一线78.1% vs 复发54.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To assess efficacy of radioimmunotherapy (RIT) in follicular lymphoma, data from 281 patients collected in the RIT Network, with a median follow-up of 8·2 years after RIT were analysed. RIT was given at first line in 18·5% and at relapse in 81·5%. Following first line therapy, 76·9% achieved complete remission (CR), 9·6% partial remission (PR), 1·9% stable disease (SD) and 1·9% had progressive disease (PD); response was not documented in 9·7%. At relapse, the rate of CR was 48·5% and that of PR was 16·6%, SD 2·6% and PD 10·5%; response was not documented in 21·8%. After median follow-up of 8·2 years, median progression-free survival (PFS) for all was 2·54 years, median overall survival (OS) was not reached. Median PFS and OS (both not reached) were significantly better in first line, compared to RIT at relapse (PFS, 2·11 years; OS, 10·8 years; P = 0·0037 and P = 0·0021, respectively). Overall 8-year PFS was 33·9%, 53·6% for first line and 29·6% for relapsed individuals. Overall 8-year OS was 58·8%, 78·1% for first line and 54·5% for relapsed patients. Thirty-five patients (12·5%) developed secondary malignancy and 16 patients (5·7%) experienced transformation into aggressive lymphoma. RIT is a safe and effective treatment option for follicular lymphoma, both at front line and relapse with an 8-year PFS of 53·6% and 29·6%, respectively.
引用
- Hohloch K, Windemuth-Kieselbach C, Kolz J, et al. Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry. Br J Haematol. 2018. PMID: 30515751. doi:10.1111/bjh.15712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。